Loading...
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
PT2385 is a first-in-class, selective small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) developed for the treatment of advanced clear cell renal cell carcinoma. Preclinical results demonstrated that PT2385 has potent antitumor efficacy in mouse xenograft models of kidney cancer. It al...
Na minha lista:
| Udgivet i: | Drug Metab Dispos |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
The American Society for Pharmacology and Experimental Therapeutics
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5829541/ https://ncbi.nlm.nih.gov/pubmed/29363499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.117.079723 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|